Upadacitinib通过抑制NF-κ b及其下游细胞因子减轻脂多糖和盲肠结扎和穿刺诱导的炎症反应。

IF 4.1 2区 医学 Q2 IMMUNOLOGY
Journal of Inflammation Research Pub Date : 2025-09-10 eCollection Date: 2025-01-01 DOI:10.2147/JIR.S535747
Qi Yao, Xueting Yang, Hongli Yan, Yang Wang, Yanlin Ma, Ning Xu
{"title":"Upadacitinib通过抑制NF-κ b及其下游细胞因子减轻脂多糖和盲肠结扎和穿刺诱导的炎症反应。","authors":"Qi Yao, Xueting Yang, Hongli Yan, Yang Wang, Yanlin Ma, Ning Xu","doi":"10.2147/JIR.S535747","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Upadacitinib (UPA) is a selective tyrosine kinase 1 (JAK-1) inhibitor, which has been applied to treat atopic dermatitis, psoriatic arthritis, and ulcerative colitis in clinic. Whether it can treat sepsis remains unclear. Here, we investigate the effect of UPA on lipopolysaccharide (LPS)- and cecal ligation and puncture (CLP)-induced inflammatory responses in vitro and in vivo.</p><p><strong>Methods: </strong>In vitro, LPS-treated RAW264.7 cell line, LPS-treated TLR4 knock-out (TLR4<sup>-/-</sup>) RAW264.7 cell line, and LPS-treated NLRP3 knock-out (NLRP3<sup>-/-</sup>) RAW264.7 cell line were used. In vivo, CLP-treated mice and CLP-treated TLR4<sup>-/-</sup> mice were used. Proteomics was used to screen inflammation-related differential proteins in RAW264.7 cells after treatments. After that, Western blotting was used to investigate the potential mechanism.</p><p><strong>Results: </strong>In vitro, UPA significantly inhibited TLR4/NF-κB and JAK/STAT pathway in the LPS-treated RAW264.7 cells. In addition, UPA reduced protein expressions of NF-κB and its downstream inflammatory cytokines such as TNF-α, IL-1β in the LPS-treated TLR4<sup>-/-</sup> RAW264.7 cells. In vivo, UPA markedly protected the sepsis mice, decreased intestinal injuries, reduced bacterial load, and downregulated the TLR4/NF-κB and JAK/STAT pathways-related proteins in macrophages isolated from peritoneal lavage fluids (PLFs) of the sepsis mice. In fact, UPA still exerted the protective effect in the CLP-treated TLR4<sup>-/-</sup> mice. The proteomics revealed that NOD-like receptor (NLR) signaling was one of the most significantly affected pathways between the LPS-treated and UPA-treated. Although UPA significantly reduced NLRP3 and IL-1β protein expressions in the LPS-treated RAW264.7 cells, its anti-inflammatory effect was not significantly abolished in the LPS-treated NLRP3<sup>-/-</sup> RAW264.7 cells.</p><p><strong>Conclusion: </strong>Taken together, UPA inhibits the LPS- and CLP-induced inflammatory responses in vitro and in vivo, which is associated with the inhibition of NF-κB and its downstream cytokines.</p>","PeriodicalId":16107,"journal":{"name":"Journal of Inflammation Research","volume":"18 ","pages":"12533-12548"},"PeriodicalIF":4.1000,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12433660/pdf/","citationCount":"0","resultStr":"{\"title\":\"Upadacitinib Attenuates Lipopolysaccharide- and Cecal Ligation and Puncture-Induced Inflammatory Responses by Inhibiting NF-κB and Its Downstream Cytokines.\",\"authors\":\"Qi Yao, Xueting Yang, Hongli Yan, Yang Wang, Yanlin Ma, Ning Xu\",\"doi\":\"10.2147/JIR.S535747\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Upadacitinib (UPA) is a selective tyrosine kinase 1 (JAK-1) inhibitor, which has been applied to treat atopic dermatitis, psoriatic arthritis, and ulcerative colitis in clinic. Whether it can treat sepsis remains unclear. Here, we investigate the effect of UPA on lipopolysaccharide (LPS)- and cecal ligation and puncture (CLP)-induced inflammatory responses in vitro and in vivo.</p><p><strong>Methods: </strong>In vitro, LPS-treated RAW264.7 cell line, LPS-treated TLR4 knock-out (TLR4<sup>-/-</sup>) RAW264.7 cell line, and LPS-treated NLRP3 knock-out (NLRP3<sup>-/-</sup>) RAW264.7 cell line were used. In vivo, CLP-treated mice and CLP-treated TLR4<sup>-/-</sup> mice were used. Proteomics was used to screen inflammation-related differential proteins in RAW264.7 cells after treatments. After that, Western blotting was used to investigate the potential mechanism.</p><p><strong>Results: </strong>In vitro, UPA significantly inhibited TLR4/NF-κB and JAK/STAT pathway in the LPS-treated RAW264.7 cells. In addition, UPA reduced protein expressions of NF-κB and its downstream inflammatory cytokines such as TNF-α, IL-1β in the LPS-treated TLR4<sup>-/-</sup> RAW264.7 cells. In vivo, UPA markedly protected the sepsis mice, decreased intestinal injuries, reduced bacterial load, and downregulated the TLR4/NF-κB and JAK/STAT pathways-related proteins in macrophages isolated from peritoneal lavage fluids (PLFs) of the sepsis mice. In fact, UPA still exerted the protective effect in the CLP-treated TLR4<sup>-/-</sup> mice. The proteomics revealed that NOD-like receptor (NLR) signaling was one of the most significantly affected pathways between the LPS-treated and UPA-treated. Although UPA significantly reduced NLRP3 and IL-1β protein expressions in the LPS-treated RAW264.7 cells, its anti-inflammatory effect was not significantly abolished in the LPS-treated NLRP3<sup>-/-</sup> RAW264.7 cells.</p><p><strong>Conclusion: </strong>Taken together, UPA inhibits the LPS- and CLP-induced inflammatory responses in vitro and in vivo, which is associated with the inhibition of NF-κB and its downstream cytokines.</p>\",\"PeriodicalId\":16107,\"journal\":{\"name\":\"Journal of Inflammation Research\",\"volume\":\"18 \",\"pages\":\"12533-12548\"},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2025-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12433660/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Inflammation Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/JIR.S535747\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Inflammation Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/JIR.S535747","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:Upadacitinib (UPA)是一种选择性酪氨酸激酶1 (JAK-1)抑制剂,临床上已应用于治疗特应性皮炎、银屑病关节炎和溃疡性结肠炎。它是否能治疗败血症尚不清楚。在这里,我们在体外和体内研究了UPA对脂多糖(LPS)和盲肠结扎和穿刺(CLP)诱导的炎症反应的影响。方法:采用体外lps处理的RAW264.7细胞株、lps处理的TLR4敲除(TLR4-/-) RAW264.7细胞株和lps处理的NLRP3敲除(NLRP3-/-) RAW264.7细胞株。在体内,使用clp处理的小鼠和clp处理的TLR4-/-小鼠。采用蛋白质组学方法筛选治疗后RAW264.7细胞中炎症相关差异蛋白。之后采用免疫印迹法研究其潜在的作用机制。结果:UPA在体外显著抑制lps处理的RAW264.7细胞的TLR4/NF-κB和JAK/STAT通路。此外,UPA可降低lps处理的TLR4-/- RAW264.7细胞中NF-κ b及其下游炎症因子TNF-α、IL-1β的蛋白表达。在体内,UPA能显著保护脓毒症小鼠,减轻肠道损伤,减少细菌负荷,下调脓毒症小鼠腹腔灌洗液(PLFs)巨噬细胞中TLR4/NF-κB和JAK/STAT通路相关蛋白。事实上,UPA在clp处理的TLR4-/-小鼠中仍然发挥着保护作用。蛋白质组学显示,nod样受体(NLR)信号通路是lps处理和upa处理之间受影响最显著的途径之一。虽然UPA在lps处理的RAW264.7细胞中显著降低了NLRP3和IL-1β蛋白的表达,但在lps处理的NLRP3-/- RAW264.7细胞中,UPA的抗炎作用并未明显减弱。结论:综上所述,UPA在体外和体内均能抑制LPS和clp诱导的炎症反应,其作用机制可能与抑制NF-κ b及其下游细胞因子有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Upadacitinib Attenuates Lipopolysaccharide- and Cecal Ligation and Puncture-Induced Inflammatory Responses by Inhibiting NF-κB and Its Downstream Cytokines.

Upadacitinib Attenuates Lipopolysaccharide- and Cecal Ligation and Puncture-Induced Inflammatory Responses by Inhibiting NF-κB and Its Downstream Cytokines.

Upadacitinib Attenuates Lipopolysaccharide- and Cecal Ligation and Puncture-Induced Inflammatory Responses by Inhibiting NF-κB and Its Downstream Cytokines.

Upadacitinib Attenuates Lipopolysaccharide- and Cecal Ligation and Puncture-Induced Inflammatory Responses by Inhibiting NF-κB and Its Downstream Cytokines.

Background: Upadacitinib (UPA) is a selective tyrosine kinase 1 (JAK-1) inhibitor, which has been applied to treat atopic dermatitis, psoriatic arthritis, and ulcerative colitis in clinic. Whether it can treat sepsis remains unclear. Here, we investigate the effect of UPA on lipopolysaccharide (LPS)- and cecal ligation and puncture (CLP)-induced inflammatory responses in vitro and in vivo.

Methods: In vitro, LPS-treated RAW264.7 cell line, LPS-treated TLR4 knock-out (TLR4-/-) RAW264.7 cell line, and LPS-treated NLRP3 knock-out (NLRP3-/-) RAW264.7 cell line were used. In vivo, CLP-treated mice and CLP-treated TLR4-/- mice were used. Proteomics was used to screen inflammation-related differential proteins in RAW264.7 cells after treatments. After that, Western blotting was used to investigate the potential mechanism.

Results: In vitro, UPA significantly inhibited TLR4/NF-κB and JAK/STAT pathway in the LPS-treated RAW264.7 cells. In addition, UPA reduced protein expressions of NF-κB and its downstream inflammatory cytokines such as TNF-α, IL-1β in the LPS-treated TLR4-/- RAW264.7 cells. In vivo, UPA markedly protected the sepsis mice, decreased intestinal injuries, reduced bacterial load, and downregulated the TLR4/NF-κB and JAK/STAT pathways-related proteins in macrophages isolated from peritoneal lavage fluids (PLFs) of the sepsis mice. In fact, UPA still exerted the protective effect in the CLP-treated TLR4-/- mice. The proteomics revealed that NOD-like receptor (NLR) signaling was one of the most significantly affected pathways between the LPS-treated and UPA-treated. Although UPA significantly reduced NLRP3 and IL-1β protein expressions in the LPS-treated RAW264.7 cells, its anti-inflammatory effect was not significantly abolished in the LPS-treated NLRP3-/- RAW264.7 cells.

Conclusion: Taken together, UPA inhibits the LPS- and CLP-induced inflammatory responses in vitro and in vivo, which is associated with the inhibition of NF-κB and its downstream cytokines.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Inflammation Research
Journal of Inflammation Research Immunology and Microbiology-Immunology
CiteScore
6.10
自引率
2.20%
发文量
658
审稿时长
16 weeks
期刊介绍: An international, peer-reviewed, open access, online journal that welcomes laboratory and clinical findings on the molecular basis, cell biology and pharmacology of inflammation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信